- UP421 is an early experimental cell therapy — not approved, not available, and years from patients.
- If a therapy like this were approved, it would almost certainly be covered under Medicare Part B (the medical benefit), not Part D, because it's administered in a clinic — not picked up at a pharmacy.
- Part B typically pays 80% after the deductible, leaving 20% coinsurance — which is why Medigap or Medicare Advantage matters enormously for high-cost one-time therapies.
You've probably seen the headlines: an experimental therapy called UP421 from Sana Biotechnology (Nasdaq: SANA) kept gene-edited, insulin-producing cells alive in a person with type 1 diabetes for 14 months — without any immune-suppressing drugs. It's early, it's a single patient, and it is not an available treatment.
But it raises a question worth answering now, while there's time to understand it: if a one-time cell therapy like this ever gets FDA approval, how would Medicare cover it? The answer surprises a lot of people — and it probably isn't Part D.
First, the therapy itself (briefly)
UP421 is a cell therapy, not a pill or an injection you take at home. Donor islet cells are genetically edited in a lab to be invisible to the immune system, then transplanted into the patient's forearm muscle, where they produce insulin in response to meals. It's in first-in-human Phase 1 testing. No insulin independence has been demonstrated, and the scalable version of the therapy hasn't started clinical trials. Realistically, any approved product is years away.
Why it wouldn't be a Part D drug
Medicare Part D covers outpatient prescription drugs — medications you pick up at a pharmacy or receive by mail and take yourself. UP421 doesn't fit that model at all:
- It's manufactured from living cells, prepared in a specialized facility.
- It's administered by clinicians in a medical setting — more like a transplant procedure than a prescription fill.
- You don't take it home, refill it, or manage dosing yourself.
Therapies like this fall under Medicare Part B — the medical benefit that covers doctor-administered drugs and procedures. There's precedent. Tzield (teplizumab), the FDA-approved therapy that can delay type 1 diabetes onset, is given as a 14-day IV infusion in a clinical setting — a Part B drug, not Part D. Lantidra (donislecel), the FDA-approved donor islet cell therapy for type 1 diabetes (approved June 2023), is likewise administered by infusion in a medical facility. If UP421 or its successor were ever approved, Part B is where coverage would almost certainly land.
What Part B coverage means for your costs
This is the part that matters for your wallet. Under Original Medicare Part B:
- After you meet the annual Part B deductible, Medicare typically pays 80% of the approved amount for covered services — and you owe the remaining 20% as coinsurance.
- Part B has no annual out-of-pocket cap.
For routine infusions, 20% is manageable. But cell and gene therapies are among the most expensive treatments in medicine — one-time therapies in other diseases have carried list prices in the hundreds of thousands to millions of dollars. At those prices, 20% coinsurance could be financially devastating without supplemental coverage.
That's exactly why Medigap (Medicare Supplement) or a Medicare Advantage plan's out-of-pocket maximum matters so much. Medigap plans typically cover the 20% Part B coinsurance. Medicare Advantage plans cap your annual out-of-pocket spending (the limit varies by plan). If transformative one-time therapies become common, the quality of your supplemental coverage may matter more than your drug plan.
The bigger picture: one-time "cures" vs. a drug-benefit system
There's a structural tension worth understanding. Part D was designed for ongoing prescriptions — drugs you take month after month, with costs spread over time. A one-time cell therapy that restores insulin production doesn't fit that model: there's no refill, no monthly copay, no formulary tier in the traditional sense.
Medicare has been wrestling with this across diseases as cell and gene therapies advance. Coverage decisions for these therapies typically involve national or local coverage determinations, evidence reviews, and sometimes special payment arrangements — a very different process from adding a drug to a Part D formulary. The system is still adapting, and seniors should expect coverage rules for curative-intent therapies to keep evolving.
What you should do today: nothing different
To be direct: UP421 changes nothing about your coverage or care right now. It is not approved, not available, and not something to ask your pharmacist about. If you have type 1 diabetes:
- Keep managing your condition with your current care team.
- During the Annual Enrollment Period (October 15 – December 7), shop your Part D and Medicare Advantage options based on the drugs you actually take today.
- If you want help understanding how Part B covers infused therapies, your State Health Insurance Assistance Program (SHIP) offers free, unbiased counseling.
But file this one away. The direction of diabetes research is unmistakable: from daily management toward durable, possibly one-time treatments. When those arrive, the coverage questions will be Part B questions — about coinsurance, Medigap, and out-of-pocket caps — not Part D formulary questions. Understanding that distinction now means you won't be caught off guard later.
This article is educational and is not medical or insurance advice. Coverage rules change; confirm specifics with Medicare (1-800-MEDICARE) or your SHIP counselor before making decisions.